Abstract
Objective
This study aims to evaluate the impact of diabetic ketoacidosis (DKA) on clinical outcomes among intensive care unit (ICU) patients diagnosed with COVID-19 and concurrent diabetes.
Methods
A retrospective analysis was conducted on ICU patients diagnosed with both COVID-19 and diabetes at a tertiary-level hospital. Patients were stratified into two groups, non-DKA and DKA, based on the presence of DKA. Comparative analyses were performed to assess clinical characteristics, laboratory parameters, treatment modalities, and prognostic outcomes between the two groups.
Results
The study included 111 ICU patients with COVID-19 and concurrent diabetes, comprising 88 patients in the non-DKA group and 23 patients in the DKA group. Compared to the non-DKA group, the DKA group exhibited a significantly higher proportion of female patients, younger age, and lower prevalence of hypertension, cardiac, and renal comorbidities (p < 0.05). The overall mortality rate was 43.5% in the DKA group, which did not significantly differ from the 55.7% observed in the non-DKA group (p = 0.336).
Conclusion
Among patients with COVID-19 and concurrent diabetes, the presence of DKA is not associated with increased mortality. This observation may be attributed to the younger age of patients in the DKA group, reduced organ support requirements, and shorter treatment duration.
Similar content being viewed by others
Data Availability
The datasets used and/or analyzed during the current study are not publicly available due to institutional restrictions but may be available from the corresponding author upon reasonable request.
References
Eskandarani RM, Sawan S. Diabetic ketoacidosis on hospitalization with COVID-19 in a previously nondiabetic patient: a review of pathophysiology. Clin Med Insights: Endocrinol Diabetes. 2020;13: 1179551420984125. https://doi.org/10.1177/1179551420984125.
Misra S, Barron E, Vamos E, Thomas S, Dhatariya K, Kar P, et al. Temporal trends in emergency admissions for diabetic ketoacidosis in people with diabetes in England before and during the COVID-19 pandemic: a population-based study. Lancet Diabetes Endocrinol. 2021;9(10):671–80. https://doi.org/10.1016/s2213-8587(21)00208-4.
Li J, Wang X, Chen J, Zuo X, Zhang H, Deng A. COVID-19 infection may cause ketosis and ketoacidosis. Diabetes Obes Metab. 2020;22(10):1935–41. https://doi.org/10.1111/dom.14057.
Baum A, Schwartz MD. Admissions to veterans affairs hospitals for emergency conditions during the COVID-19 pandemic. JAMA. 2020;324(1):96–9. https://doi.org/10.1001/jama.2020.9972.
Kamrath C, Mönkemöller K, Biester T, Rohrer TR, Warncke K, Hammersen J, et al. Ketoacidosis in children and adolescents with newly diagnosed type 1 diabetes during the COVID-19 pandemic in Germany. JAMA. 2020;324(8):801–4. https://doi.org/10.1001/jama.2020.13445.
Alaqeel A, Aljuraibah F, Alsuhaibani M, Huneif M, Alsaheel A, Dubayee MA, et al. The impact of COVID-19 pandemic lockdown on the incidence of new-onset type 1 diabetes and ketoacidosis among Saudi children. Front Endocrinol (Lausanne). 2021;12: 669302. https://doi.org/10.3389/fendo.2021.669302.
Pal R, Banerjee M, Yadav U, Bhattacharjee S. Clinical profile and outcomes in COVID-19 patients with diabetic ketoacidosis: a systematic review of literature. Diabetes Metab Syndr. 2020;14(6):1563–9. https://doi.org/10.1016/j.dsx.2020.08.015.
Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, transmission, diagnosis, and treatment of Coronavirus Disease 2019 (COVID-19): a review. JAMA. 2020;324(8):782–93. https://doi.org/10.1001/jama.2020.12839.
ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, et al. 2. Classification and diagnosis of diabetes: standards of care in diabetes-2023. Diabetes Care. 2023;46(Suppl 1):S19-s40. https://doi.org/10.2337/dc23-S002.
Umpierrez GE, Davis GM, ElSayed NA, Fadini GP, Galindo RJ, Hirsch IB, et al. Hyperglycaemic crises in adults with diabetes: a consensus report. Diabetologia. 2024;67(8):1455–79. https://doi.org/10.1007/s00125-024-06183-8.
Chan YH. Biostatistics 102: quantitative data–parametric & non-parametric tests. Singapore Med J. 2003;44(8):391–6.
Chan YH. Biostatistics 103: qualitative data - tests of independence. Singapore Med J. 2003;44(10):498–503.
Lizzo JM, Goyal A, Gupta V. Adult diabetic ketoacidosis. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023. Available from: https://www.ncbi.nlm.nih.gov/books/NBK560723/.
Wang A, Zhao W, Xu Z, Gu J. Timely blood glucose management for the outbreak of 2019 novel coronavirus disease (COVID-19) is urgently needed. Diabetes Res Clin Pract. 2020;162: 108118. https://doi.org/10.1016/j.diabres.2020.108118.
Drucker DJ. Coronavirus infections and type 2 diabetes-shared pathways with therapeutic implications. Endocrine reviews. 2020;41(3): bnaa011. https://doi.org/10.1210/endrev/bnaa011.
Lazzerini M, Barbi E, Apicella A, Marchetti F, Cardinale F, Trobia G. Delayed access or provision of care in Italy resulting from fear of COVID-19. Lancet Child Adolesc Health. 2020;4(5):e10–1. https://doi.org/10.1016/S2352-4642(20)30108-5.
Darenskaya MA, Kolesnikova LI, Kolesnikov SI. Oxidative stress: pathogenetic role in diabetes mellitus and its complications and therapeutic approaches to correction. Bull Exp Biol Med. 2021;171(2):179–89. https://doi.org/10.1007/s10517-021-05191-7.
Muniyappa R, Gubbi S. COVID-19 pandemic, coronaviruses, and diabetes mellitus. Am J Physiol Endocrinol Metab. 2020;318(5):E736–41. https://doi.org/10.1152/ajpendo.00124.2020.
Lian J, Jin X, Hao S, Cai H, Zhang S, Zheng L, et al. Analysis of epidemiological and clinical features in older patients with Coronavirus Disease 2019 (COVID-19) outside Wuhan. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2020;71(15):740–7. https://doi.org/10.1093/cid/ciaa242.
Birkebaek NH, Kamrath C, Grimsmann JM, Aakesson K, Cherubini V, Dovc K, et al. Impact of the COVID-19 pandemic on long-term trends in the prevalence of diabetic ketoacidosis at diagnosis of paediatric type 1 diabetes: an international multicentre study based on data from 13 national diabetes registries. Lancet Diabetes Endocrinol. 2022;10(11):786–94. https://doi.org/10.1016/S2213-8587(22)00246-7.
Stevens JS, Bogun MM, McMahon DJ, Zucker J, Kurlansky P, Mohan S, et al. Diabetic ketoacidosis and mortality in COVID-19 infection. Diabetes Metab. 2021;47(6): 101267. https://doi.org/10.1016/j.diabet.2021.101267.
Funding
No funding was received for this research.
Author information
Authors and Affiliations
Contributions
All authors contributed to the study design and manuscript preparation. Specific roles include drafting, data collection, analysis, and supervision.
Corresponding authors
Ethics declarations
Ethics approval and informed consent
The study was approved by the Ethics Committee of Nanfang Hospital of Southern Medical University (Ethics Approval Number: NFEC-202212-K7). Informed consent was waived due to the retrospective nature of the study.
Conflict of interest
The authors declare no conflicts of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
ESM 1
(DOCX 73.8 KB)
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Liu, L., He, Z., Tao, S. et al. Evaluation of the impact of diabetic ketoacidosis on the outcomes of ICU patients with COVID-19 and concurrent diabetes: A single-center retrospective cohort study. Int J Diabetes Dev Ctries (2025). https://doi.org/10.1007/s13410-025-01468-z
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s13410-025-01468-z